Confirmed Presenting Companies
32 innovative early-stage presenters now confirmed!
Visit this page often for the latest details
Accord Biomaterials, Inc. develops vascular devices incorporating Nogen™ nitric oxide technology to reduce clotting, infection and healing complications.
|
Advanced Cardiac Therapeutics is developing the world's first intelligent irrigated cardiac ablation catheter. This chip catheter based technology will provide the cardiologist for the first time, complete real-time control of cardiac ablations.
|
Allvivo Vascular develops biomimetic coating solutions for vascular devices. AVI’s ProteoGuard® stent technology reduces restenosis without the need for long-term dual antiplatelet therapy.
|
BIOSEAL ADVANCED Powder by PRO QR is a non-prescription topical powder that controls external bleeding from vascular access procedures, percutaneous catheters or tubes. The powder’s ingredients are a hydrophilic polymer and potassium iron oxyacid salt.
|
Cardiogenesis is a global leader of innovative therapies for ischemic cardiac disease and has received CE mark approval for a combination TMR plus bone marrow aspirate concentration delivery system. |
CardioSolutions Inc. is developing a less invasive, percutaneous alternative to open surgical repair of the heart's mitral valve. CardioSolutions Percu–Pro System™ is designed to greatly reduce the degree of mitral regurgitation in patients with either functional or degenerative valve insufficiency. |
Cardious is developing an aortic valve bypass graft system - a minimally invasive, beating heart alternative to traditional aortic valve replacement therapy.
|
The company’s core product is the Hexalon™ System, which is indicated to hold cardiac and vascular tissue during surgical procedures. |
CyberHeart Incorporated is developing the first non-invasive robotic ablation treatment for cardiac arrhythmias, such as atrial fibrillation or ventricular tachycardia. The CyberHeart system is designed to address these conditions by dynamically detecting, tracking and compensating for movement of the heart and patient, to ensure accuracy in the delivery of radiation.
|
Embrella Cardiovascular™, Inc. is developing an aortic embolic deflection device to provide cerebral protection during cardiovascular procedures. |
Endovalve Inc is developing a mitral valve replacement system designed for insertion during a minimally invasive surgical (MIS) procedure that will avoid the risks and complications usually associated with sternotomy and cardio-pulmonary bypass during open-heart surgery.
|
Heart Test Laboratories Inc. (HTL) is an early-stage, rapidly developing, U.S.-based medical device company which has developed the MyoVista, a noninvasive 90-second Myocardial Ischemia screening device with a current 93% or better correlation to an invasive angiogram.
|
The Kips Bay Mesh is intended to improve the patency of the saphenous vein graft in bypass surgery, by preventing graft dilatation and maintaining optimal blood flow characteristics. |
Lumen Biomedical is developing and commercializing unique devices that can be used in any anatomical area where embolic protection may be required. The FiberNet® System features a three-dimensional matrix of polymeric fibers for better embolic capture and conformability, and efficient retrieval is accomplished with the Xtract™ aspiration catheter. |
Novel angioplasty treatment for artery disease. |
Technology invented by cardiac surgeons that enables beating heart, sternal sparing implantation of artificial mitral chordea tendinae.
|
NeuroInterventions is a Pittsburgh-based company which designs and manufactures advanced catheter systems used to find, trap, and extract thrombus (“blood clots”) in a wide range of cerebral vessels.
|
On-X® Heart Valves: a quantum leap in mechanical valve technology. Breakthrough carbon technology and valve design provide reduced turbulence and morbid event rates rivaling tissue valves. FDA-approved PROACT (Reduced Anticoagulation) trial is in progress. |
Paracor Medical, Inc. is a venture capital-backed medical device company with a product focus on heart failure (HF). The company's HeartNet™ system reduces the size of the enlarged heart, the hallmark of systolic HF, thus addressing the underlying cause of HF rather than its symptoms. |
Revolutionizing the treatment of serious infectious diseases and cardiovascular disorders with biomimetics. |
ProRhythm’s principal therapeutic application is the treatment of mitral valve insufficiency. ProRhythm uses a disposable Catheter which delivers ultrasound energy; this heats the mitral annulus causing limited shrinkage and better closure of the valve. |
QuantumCor is developing a percutaneous mitral valve repair technology that will move valve repair from open heart surgery to a minimally invasive cardiac cath lab procedure. Unique to QuantumCor, we treat the valve directly, do not leave hardware in the heart or vascular system and provide the opportunity for late stage adjustment. |
Svelte Medical is developing a low profile Stent-on-a-Wire to reduce procedure time and cost, and a non-polymeric DES. |
Symetis, a Swiss-based company, is developing a second-generation percutaneous heart valve. The unique features of its system include tolerance upon delivery and self-positioning. |
Transcardiac Therapeutics Inc. has developed a pipeline of minimally invasive products that replace the need for open heart surgeries.
|
TyRx's implantable combination drug/device products include the AIGISRx™ Anti-Bacterial Envelope, which securely holds a pacemaker or implantable cardioverter defibrillator.
|
USB Medical has developed two patent-pending products to make cardiothoracic surgery easier, quicker and safer – the MonoFib One-Handed Defibrillation System and HV Heart Retractor. |
All the advantages of a true tissue valve, but with an MIS exchangeable leaflet set. The Lifetime Tissue Valve™ for patients of all ages.
|
VasoGenix is developing its proprietary synthetic analog of Calcitonin Gene Related Peptide for the treatment of acute heart failure.
|
Interested in becoming a presenter at insynCVentures 2009?
Click here | BECOME A PRESENTER | for more details